🇺🇸 FDA

Company profile · Sponsor

Protalix

Protalix BioTherapeutics

PLX · NYSE biotech HACKENSACK, NJ, USA
Pipeline
21
Drugs
0
Patents
8

Quick answer

Protalix (PLX) is a biotech company. headquartered in HACKENSACK, NJ, USA. listed on NYSE. NovaPharmaNews links 21 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker PLX
Exchange NYSE
Company type biotech
Headquarters HACKENSACK, NJ, USA
SEC CIK 0001006281

Pipeline (21)

Search pipeline →

  1. PL2200 Aspirin Capsules

    Protalix

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  2. PRX-102

    Protalix

    Fabry Disease

    phase 3 small molecule completed

    2 trials

  3. PRX-102 (pegunigalsidase alfa)

    Protalix

    Fabry Disease

    phase 3 mab completed

    3 trials

  4. Pegunigalsidase alfa

    Protalix

    Fabry Disease

    phase 3 mab completed

    1 trial

  5. AIR DNase™

    Protalix

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  6. Ibuprofen-PC

    Protalix

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  7. Naproxen

    Protalix

    Healthy Volunteers

    phase 2 small molecule completed

    1 trial

  8. OPRX-106

    Protalix

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. PL2200

    Protalix

    Gastroduodenal Ulceration

    phase 2 small molecule completed

    1 trial

  10. PL3100

    Protalix

    Gastroduodenal Ulcerations

    phase 2 small molecule completed

    1 trial

  11. PRX-112

    Protalix

    Gaucher Disease

    phase 2 small molecule completed

    2 trials

  12. PRX-115

    Protalix

    Gout

    phase 2 mab active

    2 trials

  13. acetylsalicylic acid

    Protalix

    Upper Gastrointestinal Mucosal Damage

    phase 2 small molecule completed

    1 trial

  14. AIR DNase

    Protalix

    Cystic Fibrosis (CF)

    phase 1 small molecule completed

    1 trial

  15. Aspirin

    Protalix

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  16. Human Glucocerebrosidase (prGCD)

    Protalix

    Gaucher Disease

    phase 1 small molecule completed

    1 trial

  17. OPRX-106

    Protalix

    Human Volunteer

    phase 1 small molecule completed

    1 trial

  18. PL2200 fasted

    Protalix

    Healthy

    phase 1 small molecule completed

    1 trial

  19. PRX-105

    Protalix

    Organophosphate Exposure

    phase 1 small molecule completed

    1 trial

  20. Pharmaceutical-lipid aspirin (PL-ASA)

    Protalix

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  21. PL-ASA

    Protalix

    Healthy Volunteers

    approved small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12194079

    Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11814657

    Modified DNase and uses thereof

    Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11225648

    Modified DNase and uses thereof

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10870842

    Stabilized alpha-galactosidase and uses thereof

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10730925

    Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10280414

    Stabilized α-galactosidase and uses thereof

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10087232

    Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Protalix?

Protalix (PLX) is a biotech company. headquartered in HACKENSACK, NJ, USA. listed on NYSE. NovaPharmaNews links 21 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Protalix sponsor?

We track 21 ClinicalTrials.gov-linked programs for Protalix, including PL2200 Aspirin Capsules and 20 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Protalix company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.